SLCO1B1*5 behind statin-induced adverse effects

By  

Reactions Weekly, Vol. 1, Iss. 1277, 2009-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Statin-induced myopathy: a review and update

By Abd Thura T   Jacobson Terry A  

Expert Opinion on Drug Safety, Vol. 10, Iss. 3, 2011-05 ,pp. : 373-387

Informa Healthcare

Access to resources Recommend Favorite

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy: Implications for Risk Assessment, Prevention and Treatment

By Chatzizisis Yiannis S.   Koskinas Konstantinos C.  

Drug Safety, Vol. 33, Iss. 3, 2010-03 ,pp. : 171-187

Adis International

Access to resources Recommend Favorite

Statin-induced myopathy: minimize the risk and manage according to symptoms and creatine kinase levels

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 10, 2010-10 ,pp. : 21-23

Adis International

Access to resources Recommend Favorite

Global analysis of genetic variation in SLCO1B1

By Pasanen Marja K   Neuvonen Pertti J   Niemi Mikko  

Pharmacogenomics, Vol. 9, Iss. 1, 2008-01 ,pp. : 19-33

Future Medicine

Access to resources Recommend Favorite